Repare Therapeutics has out-licensed its discovery platforms to newly-launched DCx Biotherapeutics for $4 million upfront plus equity stake and potential milestone payments, allowing Repare to focus on its clinical-stage oncology assets.
Repare Therapeutics is set to report Phase 2 dose expansion data for lunresertib plus camonsertib in platinum-resistant ovarian and endometrial cancers in December.
Repare Therapeutics presented Phase 1/2 TRESR trial data on camonsertib monotherapy at ESMO 2024, highlighting its potential in advanced solid tumors with ATM loss-of-function.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.